Atlas FDA

BAYER VERSANT (TM) HCV RNA 3.0 ASSAY (BDNA)

FDA premarket approval P020022 · decided 2003-03-28

Approval details

PMA number
P020022
Trade name
BAYER VERSANT (TM) HCV RNA 3.0 ASSAY (BDNA)
Generic name
Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Applicant
Siemens Healthcare Diagnostics, Inc.
Date received
2002-06-19
Decision date
2003-03-28
Days to decision
282 days
Decision code
APWD
Product code
MZP
Advisory committee
Microbiology
Expedited review
Yes
Location
Berkeley, CA
Statement
APPROVAL FOR THE BAYER VERSANT HCV RNA 3.0 ASSAY (BDNA). THE DEVICE IS INDICATED FOR: THE VERSANT HCV RNA 3.0 ASSAY (BDNA) IS A SIGNAL AMPLIFICATION NUCLEIC ACID PROBE ASSAY FOR THE QUANTITATION OF HUMAN HEPATITIS C VIRAL RNA (HCV RNA) IN THE SERUM OR PLASMA (EDTA AND ACD) OF HCV-INFECTED INDIVIDUALS USING THE BAYER SYSTEM 340 BDNA ANALYZER. SPECIMENS CONTAINING HCV GENOTYPES 1-6 HAVE BEEN VALIDATED FOR QUANTITATION IN THE ASSAY. THE VERSANT HCV RNA 3.0 ASSAY IS INTENDED FOR USE AS AN AID IN THE

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Atellica CH Acetaminophen 2 (ACTM) (K261364)Siemens Healthcare Diagnostics, Inc.2026-07-24
Atellica CH Diazo Total Bilirubin (D_TBil) (K251998)Siemens Healthcare Diagnostics, Inc.2026-02-27
Atellica® IM TSH3-Ultra II (TSH3ULII) (K251543)Siemens Healthcare Diagnostics, Inc.2026-02-06
Atellica IM Total PSA II (tPSAII) (K251630)Siemens Healthcare Diagnostics, Inc.2026-01-05
ADVIA Centaur Anti-Thyroglobulin II (aTgII) (K250816)Siemens Healthcare Diagnostics, Inc.2025-12-04
ADVIA Centaur Anti-Thyroid Peroxidase II (K250250)Siemens Healthcare Diagnostics, Inc.2025-10-17
Atellica IM Thyroglobulin (Tg) (K242981)Siemens Healthcare Diagnostics, Inc.2025-06-20
Atellica® CH Creatinine_3 (Crea3) (K242685)Siemens Healthcare Diagnostics, Inc.2024-12-04